In a landscape of rapid developments and technical advancements, access to accurate analysis is often the dividing line between stagnation and growth. The protein stability analysis market, pertaining to diverse fields from pharmaceutical and biopharmaceutical research to the study of emergent pathogens, is a testament to this ever-evolving ecosystem.
Rising expenditures on research and development (R&D) by pharmaceutical and biopharmaceutical companies, bolstered by an increasing number of proteomics and genomics research projects, are catapulting the protein stability analysis market into a period of significant expansion. Investments in these studies have the potential not only to substantiate the efficacy of scientific discoveries but to revolutionize the sector with resultant innovations.
Given the prevalent presence of biologics and recombinant protein therapeutics, the necessity of protein stability assessments is more recognised than ever. Our comprehensive protein stability analysis market report delivers incisive insights, market trends, and potential growth areas, arming you with the information necessary to make informed decisions in a dynamic market landscape.
COVID-19 had a significant impact on the protein stability analysis market in the initial phase since protein stability studies were conducted to assess the structure and nature of the COVID-19 virus to a great extent which helps gain a better understanding of the virus and supports the development of effective and efficient therapeutics. For instance, as per the article published in September 2022 in Stanford Medicine, elevated virus levels in the blood of COVID-19 patients in hospitals predicted the worsening of respiratory symptoms and suggest ongoing viral replication in advanced disease stages. A protein of the virus that causes COVID-19 was measured in the patient's blood during the test. Hence, such analysis showing the complications associated with COVID-19 through protein analysis will likely boost the market growth.
In the post-pandemic era, studies are still being conducted due to the emergence of different COVID-19 mutants. Since the beginning of the pandemic, the WHO has described eight variants of interest (VOIs), namely Epsilon, Zeta, Eta, Theta, Iota, Kappa, Lambda, and Mu. Currently, studies are being conducted to determine whether mutants of Omicron variants affect the virus's properties, speed of spreading, the severity of the associated disease, the performance of vaccines, or other public health and social measures and hence, the demand for protein analysis products is expected to increase. Another factor to account for are the Sars-COV-2 strains which are expected to have a positive impact on the market over the forecast period.
Factors such as rising research and development expenditure of pharmaceutical and biopharmaceutical companies, increasing proteomics and genomics research activities, and an increasing number of recombinant protein therapeutics and biologics are expected to drive the market growth over the forecast period since research studies require protein stability assessments to substantiate the results.
For instance, as per the EFPIA 2022 report, in 2021, Europe invested an estimated EUR 41,500 million (about USD 35,109 million) in pharmaceutical R&D. Thus, huge investments in R&D drive the growth of the protein stability analysis market during the forecast period. Furthermore, investments and financing in genomic research activities are projected to fuel the market as researchers seek opportunities in protein stability studies. For instance, in September 2022 NHGRI, part of the NIH, planned to fund USD 3.35 million over five years to launch the Genome Research Experiences to attract researchers into the Genomics Field to Enhance Diversity (GREAT) program. Moreover, in September 2022, a joint venture by the University of Western Australia and Proteomics International, which conducts vital work in medical, environmental, and agricultural testing of proteins received a funding of USD 2 million . The money is likely to enable the WA Proteomics Facility to upgrade its automated tools and staff, increasing output capacity to hundreds of samples.
As a result of the increase in pharmaceutical and biopharmaceutical companies' R&D expenditures, as well as the increase in the number of proteomics and genomics research activities, the protein stability analysis market is anticipated to witness growth over the forecast period. However, the high cost of protein stability analysis systems is expected to restrain the growth of this market to a certain extent.
Protein Stability Analysis Market Trends
Differential Scanning Calorimetry (DSC) is Expected to Hold a Significant Share Over the Forecast PeriodThe differential scanning calorimetry technique has been widely used in characterizing the stability of proteins in their native form by measuring the heat required to denature a particular biomolecule, like a protein. This technique determines molecules with higher thermal transition midpoints, which are considered more stable than those with lower transition midpoints. This technique is widely used in research & development and drug discovery. The DSC segment is likely to witness growth over the forecast period due to the wide advantages of DSC such as the ease and speed with which it can be used to see transitions in materials. Due to this reason, DSC is preferred over other techniques to scan and identify proteins.
The research and development in the field of protein stability using differential scanning calorimetry are driving the market growth as it showcases the ease and speed of DSC for research. According to an article published in June 2022 in the Biosensors journal, a study demonstrated the direct thermal characterization of protein samples using a new micro-electromechanical system (MEMS)-based differential scanning calorimeter (DSC). With high throughput, the MEMS calorimeter could screen many therapeutic proteins for conformational stability based on transition temperature. Hence, such advancements in DSC associated with protein analysis are likely to boost market growth over the forecast period. The importance of research and development (R&D) for the pharmaceutical industry is evidenced by the cumulative R&D expenditure in the sector. It has been observed that R&D spending is increasing each year and several pharma and biotech companies are focusing on strengthening their R&D facilities which are ultimately driving the growth of the market studied. The spending on research and development (R&D) by various pharmaceutical companies and government organizations has been increasing recently in the United States, which is anticipated to drive market growth over the forecast period. For instance, as per the 2022 report from EFPIA, in 2021 North America accounted for 49.1% of world pharmaceutical sales compared with 23.4% for Europe. As the R&D expenditure and sales increase, the demand for protein stability analysis techniques like DSC is expected to increase thereby boosting the market growth.
North America is Expected to Dominate the Market During the Forecast PeriodThe presence of well-established research and development institutions and their high investment in the region is driving market growth over the forecast period since the research initiatives are likely to utilize protein stability studies for accurate results. For instance, as per the Statistics Canada June 2022 report, in-house spending on R&D in 2021 was expected to grow by 3.5%, reaching USD 23.4 billion. Companies expect more modest growth in their in-house R&D spending in 2022, with total R&D spending anticipated to increase by 1.7% to USD 23.8 billion.
Furthermore, investments by the government and private companies in genomic and proteomic research are likely to drive market growth in the North American region. For instance, in February 2021, through a merger, Seattle-based Nautilus Biotechnology entered the public market and received USD 350 million to accelerate the development of its protein analysis technology for drug discovery and diagnostic applications. Moreover, in September 2022, Stanford University Mass Spectrometry Proteomics Seed Grants provided a research grant of USD 10,000 to researchers aiming for new mass spectrometry projects and new methodologies taking advantage of the capabilities of recently added research instrumentation.
Additionally, genomic as well as proteomic research works in the North American region promote market growth since they identify the need for protein stability study and utilize the reagents and equipment associated with stability studies. For instance, as per the article published in May 2022 by MDPI which was supported by the National Institute of Respiratory Diseases “Ismael Cosío Villegas,” Mexico, a study showed that proteomics has enabled the identification of novel allergens that can be used in serodiagnosis and has made it possible to analyze thousands of proteins in a single analysis.
Protein Stability Analysis Market Competitor AnalysisThe protein stability analysis market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well-known. These include Agilent Technologies Inc, NanoTemper Technologies, Shimadzu Corporation, Thermo Fisher Scientific, and Spectris PLC (Malvern Panalytical Ltd).
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Research and Development Expenditure of Pharmaceutical and Biopharmaceutical Companies
4.2.2 Increasing Proteomics and Genomics Research Activities
4.2.3 Increasing Number of Recombinant Protein Therapeutics and Biologics
4.3 Market Restraints
4.3.1 High Cost of Protein Stability Analysis Instruments
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Reagents and Assay Kits
5.1.3 Consumables and Accessories
5.1.4 Other Products
5.2 By Technique
5.2.3 Surface Plasmon Resonance
5.2.4 Differential Scanning Calorimetry
5.2.5 Differential Scanning Fluorimetry
5.2.6 Other Techniques
5.3 By End-User
5.3.1 Pharmaceutical & Biotechnology Companies
5.3.2 Academic and Research Organizations
5.4.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6.1.1 Agilent Technologies, Inc.
6.1.2 NanoTemper Technologies
6.1.3 Horiba, Ltd
6.1.4 Perkinelmer, Inc.
6.1.5 Setaram Instrumentation
6.1.6 Shimadzu Corporation
6.1.7 Spectris PLC
6.1.8 Thermo Fisher Scientific
6.1.9 Unchained Labs
6.1.10 Danaher Corporation (Molecular Devices)
6.1.11 Spectris PLC (Malvern Panalytical Ltd)
6.1.12 Bruker Corporation
A selection of companies mentioned in this report includes:
- Agilent Technologies, Inc.
- NanoTemper Technologies
- Horiba, Ltd
- Perkinelmer, Inc.
- Setaram Instrumentation
- Shimadzu Corporation
- Spectris PLC
- Thermo Fisher Scientific
- Unchained Labs
- Danaher Corporation (Molecular Devices)
- Spectris PLC (Malvern Panalytical Ltd)
- Bruker Corporation